Extedo claims, the version 2.0 SP1 features new Graphical User Interface (GUI), faster automatic validation set detection, new ways to add new sequences, parallel mass validation support, improved online help, CITRIX support, and enhanced reporting functionality.
EURSvalidator 2.0 SP1 minimizes the risk of failing technical validation at the regulatory authorities and ensures an improved electronic dossier lifecycle for the future.
Extedo CEO Tore Bergsteiner said the success of the electronic drug approval process in Europe is primarily based on well-defined and harmonized validation criteria.
"We continue to support this mission with EURSvalidator 2.0," Bergsteiner said.